

Resource Summary Report

Generated by [dkNET](#) on Aug 30, 2026

Wistar Histotechnology Core Facility

RRID:SCR_010206

Type: Tool

Proper Citation

Wistar Histotechnology Core Facility (RRID:SCR_010206)

Resource Information

URL: <https://www.wistar.org/resources/biomedical-research-support-facility/histotechnology/>

Proper Citation: Wistar Histotechnology Core Facility (RRID:SCR_010206)

Description: Core facility that provides the following services: Paraffin sectioning service, Frozen sectioning service, Histology staining services. This facility provides basic histology services. These include fixing, processing and paraffin embedding of all types of tissues for light microscopy (i.e. routine stains, immunohistochemistry or in situ hybridization). Routine hematoxylin and eosin staining as well as special staining is done in the lab. Slides are prepared for immunohistochemistry and in situ and immunohistochemistry. Frozen sectioning is also available. It is advisable to contact the facility about freezing techniques so the best sections can be obtained.

Synonyms: Wistar Histotechnology Facility

Resource Type: access service resource, core facility, service resource

Keywords: tissue sectioning, histological sample preparation, cryosectioning, frozen block embedding, histology, hematoxylin and eosin stain, staining

Resource Name: Wistar Histotechnology Core Facility

Resource ID: SCR_010206

Alternate IDs: nlx_156685

Old URLs: <http://eagle-i.itmat.upenn.edu/i/0000013f-776d-64a8-a468-831a80000000>

Record Creation Time: 20220129T080257+0000

Record Last Update: 20260829T183222+0000

Ratings and Alerts

No rating or validation information has been found for Wistar Histotechnology Core Facility.

No alerts have been found for Wistar Histotechnology Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Colevas AD, et al. (2025) First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr-Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(5), 815.